Nyhuis A - Search Results

1

Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.

Molife C, Haynes VS, Nyhuis A, Faries DE, Gelwicks S, Kelsey DK, Alatorre CI. Molife C, et al. Among authors: nyhuis a. Curr Med Res Opin. 2018 Apr;34(4):619-632. doi: 10.1080/03007995.2017.1421918. Epub 2018 Feb 5. Curr Med Res Opin. 2018. PMID: 29298540

2

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia.

Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ. Faries DE, et al. Curr Med Res Opin. 2008 May;24(5):1399-405. doi: 10.1185/030079908x297385. Epub 2008 Apr 7. Curr Med Res Opin. 2008. PMID: 18397549 Clinical Trial.

3

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.

Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R. Tunis SL, et al. Value Health. 2006 Mar-Apr;9(2):77-89. doi: 10.1111/j.1524-4733.2006.00083.x. Value Health. 2006. PMID: 16626411 Free article. Clinical Trial.

4

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia.

Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ. Faries DE, et al. BMC Psychiatry. 2009 Sep 2;9:54. doi: 10.1186/1471-244X-9-54. BMC Psychiatry. 2009. PMID: 19725969 Free PMC article. Clinical Trial.

5

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.

Ascher-Svanum H, Nyhuis AW, Stauffer V, Kinon BJ, Faries DE, Phillips GA, Schuh K, Awad AG, Keefe R, Naber D. Ascher-Svanum H, et al. Among authors: nyhuis aw. Curr Med Res Opin. 2010 Oct;26(10):2403-10. doi: 10.1185/03007995.2010.515900. Curr Med Res Opin. 2010. PMID: 20812791 Clinical Trial.

6

Predictors of switching antipsychotic medications in the treatment of schizophrenia.

Nyhuis AW, Faries DE, Ascher-Svanum H, Stauffer VL, Kinon BJ. Nyhuis AW, et al. BMC Psychiatry. 2010 Sep 28;10:75. doi: 10.1186/1471-244X-10-75. BMC Psychiatry. 2010. PMID: 20920179 Free PMC article.

7

Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.

Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A. Ascher-Svanum H, et al. Among authors: nyhuis aw. Schizophr Bull. 2008 Nov;34(6):1163-71. doi: 10.1093/schbul/sbm134. Epub 2007 Dec 21. Schizophr Bull. 2008. PMID: 18156640 Free PMC article. Clinical Trial.

8

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example.

Faries DE, Nyhuis AW, Ascher-Svanum H. Faries DE, et al. Cost Eff Resour Alloc. 2009 May 27;7:11. doi: 10.1186/1478-7547-7-11. Cost Eff Resour Alloc. 2009. PMID: 19473545 Free PMC article.

9

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia.

Ascher-Svanum H, Nyhuis AW, Faries DE, Ball DE, Kinon BJ. Ascher-Svanum H, et al. BMC Psychiatry. 2010 Jan 28;10:11. doi: 10.1186/1471-244X-10-11. BMC Psychiatry. 2010. PMID: 20109170 Free PMC article. Clinical Trial.

10

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.

Faries D, Ascher-Svanum H, Phillips G, Nyhuis AW, Sugihara T, Stauffer V, Kinon BJ. Faries D, et al. BMC Med Res Methodol. 2012 Sep 13;12:142. doi: 10.1186/1471-2288-12-142. BMC Med Res Methodol. 2012. PMID: 22974273 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters